Guidance
Interesting shortcuts
EFFRA Members' Perspectives
News Dashboard
Structured Wiki
Search
FoF and Made in Europe Partnership
Demonstrators, pilots, prototypes
Exploitable result(s)
Significant innovations and lessons learned, training aspects
Report - Video - Presentation - Publication....?
Project clusters
EFFRA member perspectives
Manufacturing future products
Manufacturing performance characteristics
Technologies and enablers
ICT performance characteristics
Standards, technical committees and working groups
Contribution of R&I projects to standardisation
Regulatory and policy aspects
Standards - other classifications
Business model aspects
Pathways
MiE SRIA R&I Priorities
MiE WP26-27 Consultation - Potential Research Topics only
MiE WP26-27 Consultation and context pointers
MiE WP26-27 Consultation with pointers to WP25-27 consultation
MiE KPIs
Relevant (future) calls
EU-Programme-Call
NACE code
EFFRA Organisations - members
EFFRA WG pointers
Pathways
Pathways
Projects
Projects
Resources
Resources
Project ideas
Project ideas
People & organisations
People
Organisations
portal@effra.eu
Visit the EFFRA website
Login
Structured Wiki
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-13-two-stage
H2020-JTI-IMI2-2017-13-two-stage
IMI2-2017-13-01 Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
IMI2-2017-13-02 Genome-Environment Interactions in Inflammatory Skin Disease
IMI2-2017-13-03 The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
IMI2-2017-13-04 Mitochondrial Dysfunction in Neurodegeneration
IMI2-2017-13-05 Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative
IMI2-2017-13-06 A sustainable European induced pluripotent stem cell platform
IMI2-2017-13-07 Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
IMI2-2017-13-08 Human Tumour Microenvironment Immunoprofiling
IMI2-2017-13-09 ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now
IMI2-2017-13-10 Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
IMI2-2017-13-11 Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
IMI2-2017-13-14 Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases
IMI2-2017-13-15 Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases